A Pill, a Prescription, and a Patchwork of Laws: The Federal Failure on Medication Abortion

In the two years since the Supreme Court's decision in Dobbs v. Jackson Women's Health Organization stripped federal abortion protections from the Constitution, state legislatures have moved with remarkable speed — and remarkable inconsistency. Nowhere is the resulting chaos more visible than in the ongoing legal and political battle over medication abortion, a safe, FDA-approved method of ending a pregnancy that now accounts for the majority of abortions performed in the United States.

The drug at the center of this conflict, mifepristone, has been in continuous use in this country since 2000. It has a safety record that rivals over-the-counter medications. And yet today, its availability depends less on medical science than on geography — on which state a patient happens to live in, which pharmacy they can reach, and whether their mail carrier is permitted to deliver a sealed envelope across a state line.

This is not a healthcare policy. It is a healthcare emergency.

The Legal Landscape: A Map That Changes Every Month

Since Dobbs, more than a dozen states have enacted laws that restrict or outright ban medication abortion, either as part of broader abortion bans or through targeted restrictions on mifepristone specifically. Some states have attempted to criminalize the mailing of abortion pills into their borders, relying on a nineteenth-century statute — the Comstock Act — that was long considered a dead letter of American law. Others have imposed gestational limits, mandatory waiting periods, and in-person dispensing requirements that effectively nullify the FDA's own protocols for telemedicine prescribing.

The courts have not provided clarity. In 2023, a federal district judge in Texas issued a ruling that would have suspended FDA approval of mifepristone nationwide — a decision that sent shockwaves through the medical community before being stayed on appeal. The Supreme Court ultimately ruled that the plaintiffs in that case lacked standing, but the underlying legal questions remain unresolved. New challenges are already moving through the federal judiciary, and the outcome of any one of them could once again throw access into question for millions of Americans, regardless of the state in which they reside.

What this means in practice is that the legal status of medication abortion is not stable. It is contested terrain, relitigated in courtroom after courtroom, while patients and providers are left to navigate the uncertainty on their own.

The Human Cost of Congressional Silence

Behind the legal briefs and the appellate dockets are real people making impossible decisions.

Consider the woman in a rural state with a total abortion ban who receives a diagnosis of a nonviable pregnancy in her first trimester. She cannot access mifepristone locally. She cannot easily travel to a neighboring state. She may not be able to afford to take days off work, arrange childcare, or pay for a hotel. Her physician, fearing criminal prosecution, is unable to advise her fully. She is left to search the internet, weigh her options, and make a medical decision without adequate support — all because her state legislature has decided that her circumstances do not warrant compassion.

Or consider the healthcare provider in a state where medication abortion remains legal, but where the threat of future restrictions has made recruiting and retaining staff nearly impossible. Clinics that serve entire regions are operating with skeleton crews, appointment backlogs stretching into weeks, and administrative costs driven up by the need to monitor a legal landscape that shifts without warning.

These are not edge cases. They are the predictable consequences of allowing healthcare access to be determined by a fragmented, politically driven system of state laws rather than by consistent federal standards grounded in evidence and equity.

What Congress Can and Must Do

The argument for federal action is not merely ideological. It is structural. The FDA is a federal agency. Its drug approval process exists precisely to establish a national standard for safety and efficacy that supersedes local variation. When states enact laws that effectively countermand FDA determinations — requiring in-person dispensing when the FDA permits mail delivery, or banning a drug the FDA has approved — they are not exercising legitimate public health authority. They are substituting political judgment for scientific consensus.

Congress has the authority to address this directly. Legislation that codifies the right to access FDA-approved medications consistent with federal prescribing guidelines would establish a clear legal floor that state restrictions cannot breach. A federal shield law protecting patients who travel across state lines for reproductive care, and the providers who serve them, would close one of the most dangerous loopholes in the current legal environment. And a modernized interpretation of federal preemption doctrine — clarified through statute rather than left to the courts — would prevent the Comstock Act and similar relics from being weaponized against contemporary healthcare practice.

None of this requires a sweeping or contentious ideological statement. It requires only that Congress affirm what the FDA has already determined: that mifepristone is safe, effective, and appropriate for use in a telemedicine setting, and that patients and providers deserve the legal certainty to act on that determination without fear.

A Question of Who Congress Represents

Polling consistently shows that a majority of Americans — across party lines and across regions — believe that decisions about medication and reproductive healthcare should rest with patients and their doctors, not with state legislatures. That majority is not reflected in the current composition of Congress, nor in the legislative priorities of those who have blocked federal reproductive health protections at every turn.

Shireen for Congress is built on a different premise: that representation means accountability to the people who actually live with the consequences of policy. The women who are rationing their options, the providers who are operating under legal threat, the pharmacists who are uncertain whether filling a valid prescription could expose them to liability — these are constituents. Their experiences are data. Their needs are a mandate.

The patchwork of state laws governing medication abortion is not a stable equilibrium. It is an ongoing crisis that will deepen with every new legal challenge, every new legislative session, every new month of congressional inaction. The federal government has both the authority and the obligation to act.

The question is whether the people we send to Congress will choose to use it.